Verici DX Logo



Current approaches to categorizing patients while they are waiting on the list as low risk and high risk for rejection after transplant are very general, and include factors such as race, patients being retransplanted, the recipients age, and patients who may have antibodies against common donors. Clarava™ utilizes an RNA gene signature to help define individual patient risk for acute rejection, during the pre-transplant assessment of a patient listed for kidney transplant. This can help clinicians accurately determine the level of immunosuppression in a more personalized manner.
This product is in Clinical Validation Studies